1. Munayyer HK, et al. Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds. Antimicrob Agents Chemother 2004;48:3690–6.
2. Xiao L, et al. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother 2004;48:568–74.
3. Pfaller MA, et al. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol 2003;41:78–83.
4. Barchiesi F, et al. Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans. J Antimicrob Chemother 2001;48:769–73.
5. Cacciapuoti A, et al. In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother 2000;44:2017–22.
6. Pfaller MA, et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002;46:1032–7.
7. Pfaller MA, Messer S, Jones RN. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob Agents Chemother 1997;41:233–5.
8. Li X, et al. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother 2004;53:74–80.
9. Pfaller MA, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004;48:201–5.
10. Courtney R, et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003;47:2788–95.
11. Ullmann AJ, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50:658–66.
12. Courtney R, et al. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004;48:804–8.
13. Ezzet F, et al. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005;44:211–20.
14. Krieter P, et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004;48:3543–51.
15. Courtney R, et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol 2005;45:185–92.
16. Wexler D, et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004;21:645–53.
17. Ullmann AJ, et al. Posaconazole vs fluconazole for prophylaxis of invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC, USA, 2005.
18. Cornely OA, et al. Posaconazole vs standard azole therapy for prophylaxis of invasive fungal infections among high-risk neutropenic patients: Results of a randomized, multicenter trial. 47th Annual Meeting of the American Society of Hematology; Atlanta, USA, 2005.
19. Walsh TJ, et al. Posaconazole for treatment of invasive aspergillosis in patients who are refractory to or intolerant of conventional therapy: An externally controlled blinded trial. The American Society of Hematology. 45th Annual Meeting and Exposition; San Diego, 2003.
20. van Burik JA, et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006;42:61–5.
21. Greenberg RN, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006;50:126–33.
22. Raad II, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006;42:1398–403.
23. Negroni R, et al. Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Rev Inst Med Trop Sao Paulo 2005;47:339–46.
24. Keating GM. Posaconazole. Drugs 2005;65:1553–67; discussion 1568–9.
25. Vazquez JA, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006;42:1179–86.
26. Skiest DJ, et al. Open-label trial of posaconazole for azole-refractory oropharyngeal and esophageal candidiasis in HIV/AIDS subjects: Final analysis. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC, USA, 2004.
27. Cornely OA, et al. Posaconazole vs standard azoles as antifungal prophylaxis in neutropenic patients with acute myelogenous leukemia or myelodysplastic syndrome: Impact on mortality. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA, 2005.
28. Raad II, Graybill JR, Bustamante AB, Cornely OA, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006;42:1726–34.
Priv.-Doz. Dr. med. Oliver A. Cornely, Jörg-Janne Vehreschild, Klinikum der Universität zu Köln, Klinik I für Innere Medizin, Klinisches Studienzentrum Infektiologie II, Kerpener Straße 62, 50937 Köln, E-Mail: Oliver.firstname.lastname@example.org
Dr. med. Andrew J. Ullmann, Klinikum der Johannes Gutenberg-Universität, III. Medizinische Klinik, Langenbeckstraße 1, 55101 Mainz